Royalty Pharma Plc

RPRX · Moat type: REGULIERUNG

MoatScore

4/10

Fair Value

38 USD

Margin of Safety

-53.3 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL Royalty Pharma acquires biopharmaceutical royalties on patent-protected medications and thereby participates in the revenue of established as well as developing therapeutics without bearing responsibility for clinical trials or production itself.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.